Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJZVPB)

• Drug Name: ENMD-2076 Drug Info
• Synonyms: ENMD-2076; 934353-76-1; ENMD 2076; (E)-N-(5-Methyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-styrylpyrimidin-4-amine; UNII-J6U9WP10T7; ENMD2076; J6U9WP10T7; CHEMBL482968; 6-(4-methylpiperazin-1-yl)-N-(5-methyl-1H-pyrazol-3-yl)-2-[(E)-2-phenylethenyl]pyrimidin-4-amine; 6-(4-METHYL-1-PIPERAZINYL)-N-(5-METHYL-1H-PYRAZOL-3-YL)-2-[(1E)-2-PHENYLETHENYL]-4-PYRIMIDINAMINE; ENMD-981693; MLS006011042; SCHEMBL596481; GTPL7885; SCHEMBL15668060; SCHEMBL10122872; ENND-2076; EX-A235; DTXSID60239430; MolPort-009-679-391; AOB87159

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 2	[1]
Fibrolamellar liver cancer	2C12.02	Phase 2	[2]
Triple negative breast cancer	2C60-2C65	Phase 2	[2]
Hepatocellular carcinoma	2C12.02	Phase 1	[3]

• Cross-matching ID:
  PubChem CID: 16041424
  CAS Number: CAS 934353-76-1
  TTD Drug ID: DMJZVPB

Molecule-Related Drug Atlas

Drug(s) Targeting Protein kinase (PK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MGCD516	DM752PU	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[2]
LY2801653	DM0KJDY	Biliary tract cancer	2C17	Phase 2	[2]
MGCD265	DMRPCF2	Non-small-cell lung cancer	2C25.Y	Phase 2	[2]
RV-568	DM652CM	Asthma	CA23	Phase 2	[5]
TG02	DMZFIGQ	Anaplastic astrocytoma	2A00.0	Phase 1/2	[6]
LX-7101	DM2LYIN	Glaucoma/ocular hypertension	9C61	Phase 1/2	[7]
Cyclocreatine	DM1I7UO	Virus infection	1A24-1D9Z	Discontinued in Phase 1	[8]

Drug(s) Targeting Aurora kinase A (AURKA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AT9283	DMQ94CT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[9]
MLN8237	DMO8PT9	Solid tumour/cancer	2A00-2F9Z	Phase 3	[10]
PHA-739358	DMGYBZI	Prostate cancer	2C82.0	Phase 2	[4]
VX-680	DM93YKJ	Solid tumour/cancer	2A00-2F9Z	Phase 2	[11]
ABT-348	DMMZOYN	Haematological malignancy	2B33.Y	Phase 2	[12]
LY3295668	DM8RJTB	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[13]
HPP-607	DM5VSZR	Solid tumour/cancer	2A00-2F9Z	Phase 1	[14]
MLN8054	DMUANF3	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]
CYC116	DMUMHXT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]
AMG 900	DMASGXJ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aurora kinase A (AURKA)	TTPS3C0	AURKA_HUMAN	Inhibitor	[4]
Protein kinase (PK)	TTU8W4S	NOUNIPROTAC	Inhibitor	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7885).
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
• [5] Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Design, synthesis and biological characterization of selective LIMK inhibitors. Bioorg Med Chem Lett. 2015 Sep 15;25(18):4005-10.
• [8] Direct determination of creatine kinase equilibrium constants with creatine or cyclocreatine substrate. Biochim Biophys Acta. 1989 Oct 19;998(3):317-20.
• [9] A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. Clin Cancer Res. 2015 Jan 15;21(2):267-73.
• [10] Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models. Journal of Clinical Oncology, 2009:8553.
• [11] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [12] Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27.
• [13] Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy. Mol Cancer Ther. 2019 Dec;18(12):2207-2219.
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936).
• [15] Clinical pipeline report, company report or official report of Cyclacel.
• [16] Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res. 2010 Dec 1;70(23):9846-54.